The MU School of Medicine has joined a nationwide, at-home clinical study, ACTIV-6, to test how repurposed medications can be used to treat mild-to-moderate COVID-19 symptoms. The medications in the study are fluticasone, fluvoxamine and ivermectin, all previously approved by the U.S. Food and Drug Administration to treat other conditions. Those interested in participating in the study must be 30 years old or older, have tested positive for COVID-19 within the past 10 days and have at least two COVID-19 symptoms for seven days or less. You can find more information or enroll in the study through activ6study.org, or by...